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INVITED COMMENTARY
R. James Valentine, MD
More than 510,000 coronary bypass operations are performed
each year in the United States, but few institutions have had more
than occasional experience with coronary-subclavian steal syn-
drome. In one of the largest series of cases to date, Westerband and
colleagues, who are noted endovascular specialists, champion en-
dovascular treatment of coronary-subclavian steal. They report a
92% technical success rate, 84% primary patency rate, and 100%
assisted patency rate after left subclavian artery interventions.
However, when the data are scrutinized, the results may be less
compelling. The follow-up was not rigorous, and objective vascu-
lar tests were not performed. Mean follow-up was 29 months, and
only seven patients have been followed for more than 3 years.
Within this time frame, 3 of 13 patients undergoing endovascular
therapy have had recurrent subclavian stenosis—symptomatic in 2
patients and asymptomatic in 1 patient—for a recurrence rate of
23%. This should not be surprising, given the 3-year angioplasty
patency rate of 73% reported for endovascular treatment of all
subclavian lesions at the Arizona Heart Institute.1 These results are
also in keeping with the long-term patency rate of 70% to 84%
reported by others.
In comparison, carotid-subclavian bypass grafting is associated
with superior results. Experienced surgical groups have reported
5-year primary patency rate of 92% to 98%.2 However, operative
morbidity and mortality have generally been higher compared with
those at angioplasty. Experience with bypass grafting to treat
coronary-subclavian steal is sparse. In the only other relatively large
series of patients, all 12 patients who underwent carotid-subclavian
bypass grafting survived the operation, and all grafts were patent at
a mean of 29 months.3
What, then, is the best way to treat coronary-subclavian steal?
The dilemma balances on the trade-off between perioperative risk
and long-term results. Reduced perioperative risk clearly favors
endovascular therapy, whereas primary patency is superior after
open operation. In this population, long-term patency may be the
more important issue. Although the vast majority of recurrent
lesions can be treated at repeat angioplasty, averting this potentially
lethal problem is far preferable to repeat treatment.
In the final analysis, treatment recommendations must await
further experience with larger groups of patients who have been
followed up longer. At present, endovascular therapy seems to be
most appropriate in patients at high operative risk and with limited
life expectancy.
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